@article{6f988db369444e37a514bea98d5d87cd,
title = "Tetraspanin CD82 organizes dectin-1 into signaling domains to mediate cellular responses to candida albicans",
abstract = "Tetraspanins are a family of proteins possessing four transmembrane domains that help in lateral organization of plasma membrane proteins. These proteins interact with each other as well as other receptors and signaling proteins, resulting in functional complexes called “tetraspanin microdomains.” Tetraspanins, including CD82, play an essential role in the pathogenesis of fungal infections. Dectin-1, a receptor for the fungal cell wall carbohydrate b-1,3-glucan, is vital to host defense against fungal infections. The current study identifies a novel association between tetraspanin CD82 and Dectin-1 on the plasma membrane of Candida albicans-containing phagosomes independent of phagocytic ability. Deletion of CD82 in mice resulted in diminished fungicidal activity, increased C. albicans viability within macrophages, and decreased cytokine production (TNF-a, IL-1b) at both mRNA and protein level in macrophages. Additionally, CD82 organized Dectin-1 clustering in the phagocytic cup. Deletion of CD82 modulates Dectin-1 signaling, resulting in a reduction of Src and Syk phosphorylation and reactive oxygen species production. CD82 knockout mice were more susceptible to C. albicans as compared with wild-type mice. Furthermore, patient C. albicans-induced cytokine production was influenced by two human CD82 single nucleotide polymorphisms, whereas an additional CD82 single nucleotide polymorphism increased the risk for candidemia independent of cytokine production. Together, these data demonstrate that CD82 organizes the proper assembly of Dectin-1 signaling machinery in response to C. albicans.",
author = "Tam, {Jenny M.} and Reedy, {Jennifer L.} and Lukason, {Daniel P.} and Kuna, {Sunnie G.} and Mridu Acharya and Khan, {Nida S.} and Negoro, {Paige E.} and Shuying Xu and Ward, {Rebecca A.} and Feldman, {Michael B.} and Dutko, {Richard A.} and Jeffery, {Jane B.} and Anna Sokolovska and Wivagg, {Carl N.} and Lassen, {Kara G.} and {Le Naour}, Fran{\c c}ois and Vasiliki Matzaraki and Garner, {Ethan C.} and Xavier, {Ramnik J.} and Vinod Kumar and {Van De Veerdonk}, {Frank L.} and Netea, {Mihai G.} and Miranti, {Cindy K.} and Mansour, {Michael K.} and Vyas, {Jatin M.}",
note = "Funding Information: J.L.R.), a KL2/Catalyst Medical Research Investigator Training award (an appointed KL2 award) from Harvard Catalyst | The Harvard Clinical Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, Award KL2 TR001100 [to J.L.R.]), and National Institutes of Health Training Grant T32 HL116275 (to M.B.F.). M.G.N. was supported by a Spinoza Prize from the Netherlands Organization for Scientific Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the National Institutes of Health. Funding Information: This work was supported by National Institutes of Health Grants 5R01 AI092084 and 1R01 AI097519 (to J.M.V.), 1R01 AI132638 (to M.K.M.), and T32 A1007061-35 (to Publisher Copyright: Copyright {\textcopyright} 2019 by The American Association of Immunologists, Inc. All rights reserved.",
year = "2019",
month = jun,
day = "1",
doi = "10.4049/jimmunol.1801384",
language = "English (US)",
volume = "202",
pages = "3256--3266",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "11",
}